- Home
- QD vs ABUS Comparison
QD vs ABUS Comparison
Compare QD & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QD
- ABUS
- Stock Information
- Founded
- QD 2014
- ABUS 2005
- Country
- QD China
- ABUS United States
- Employees
- QD N/A
- ABUS N/A
- Industry
- QD Finance: Consumer Services
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- QD Finance
- ABUS Health Care
- Exchange
- QD Nasdaq
- ABUS Nasdaq
- Market Cap
- QD 761.2M
- ABUS 906.7M
- IPO Year
- QD 2017
- ABUS N/A
- Fundamental
- Price
- QD $4.78
- ABUS $4.73
- Analyst Decision
- QD
- ABUS Strong Buy
- Analyst Count
- QD 0
- ABUS 2
- Target Price
- QD N/A
- ABUS $5.00
- AVG Volume (30 Days)
- QD 331.2K
- ABUS 951.6K
- Earning Date
- QD 11-21-2025
- ABUS 11-06-2025
- Dividend Yield
- QD N/A
- ABUS N/A
- EPS Growth
- QD N/A
- ABUS N/A
- EPS
- QD 0.42
- ABUS N/A
- Revenue
- QD $19,058,373.00
- ABUS $15,416,000.00
- Revenue This Year
- QD N/A
- ABUS $138.02
- Revenue Next Year
- QD N/A
- ABUS N/A
- P/E Ratio
- QD $11.32
- ABUS N/A
- Revenue Growth
- QD N/A
- ABUS 53.23
- 52 Week Low
- QD $2.04
- ABUS $2.71
- 52 Week High
- QD $5.08
- ABUS $5.10
- Technical
- Relative Strength Index (RSI)
- QD 58.94
- ABUS 60.62
- Support Level
- QD $4.29
- ABUS $4.26
- Resistance Level
- QD $4.94
- ABUS $4.95
- Average True Range (ATR)
- QD 0.22
- ABUS 0.23
- MACD
- QD 0.02
- ABUS 0.03
- Stochastic Oscillator
- QD 75.82
- ABUS 74.56
About QD Qudian Inc. each representing one
Qudian Inc is a consumer-oriented technology company engaged in the operation of online platforms to provide small consumer credit products in the People's Republic of China. It aims to empower financial institutions with its technological capabilities, help them improve marketing and operating efficiency, and enable financial institutions to efficiently connect their diversified financial products with scene traffic across the entire network It derives a majority of its revenue from the People's Republic of China.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.